相关实验视频
Updated: Jun 14, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
因子XIIa抑制剂复合人体白蛋白Infestin-4消除了封闭性动脉血栓的形成,而不影响出血
Ina Hagedorn1, Stefan Schmidbauer, Irina Pleines
1University Clinic, University of Würzburg, 97080 Würzburg, Germany.
Circulation
|March 24, 2010
概括
一种新型的抑制剂rHA-Infestin-4在动物模型中有效地预防病理性血栓形成和缺血性中风. 这种XIIa因子抑制剂提供强大的抗血栓性保护,而不会影响血液静止.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 凝血是血液静止的重要过程,但也可能导致心肌梗塞和中风等血栓性疾病.
- 因子XII (FXII) 在病理性血栓形成中起着关键作用,但对于正常的血液静止并非必不可少.
- FXII是安全抗血栓策略的潜在治疗点.
研究的目的:
- 研究一种新型XIIa因子抑制剂rHA-Infestin-4在预防病理性血栓和缺血事件中的有效性.
- 通过评估其对血液静止的影响来评估rHA-Infestin-4的安全性.
主要方法:
- 在Infestin-4的补充DNA被融合到重组人体白蛋白 (rHA).
- 在人,小鼠和老鼠血中对rHA-Infestin-4进行因子XIIa抑制的体外分析及其对激活的部分血栓形成时间 (aPTT) 的影响.
- 在小鼠和大鼠体内研究以评估血栓形成和保护在缺血性中风模型中,以及出血分析.
主要成果:
- rHA-Infestin-4显示出XIIa因子的特定抑制,在多种物种中延长了aPTT.
- 在体内,rHA-Infestin-4完全阻止了小鼠和老鼠的动脉血栓形成.
- 在小鼠模型中,rHA-Infestin-4在维持正常血液静止的同时,在缺血性中风中提供了显著的保护.
结论:
- rHA-Infestin-4是一种强大的XIIa因子抑制剂.
- 这种药物提供了强大的保护,防止缺血性心血管和脑血管事件.
- rHA-Infestin-4代表了抗血栓治疗的有前途的治疗候选者,在血液静止方面具有有利的安全性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

